Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Stefan W. Ryter. Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury. Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021

Member's Comments

No comment yet.

Related content which might interest you: Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 Immunotherapy improves inflammatory response and lymphocyte apoptosis as a new therapeutic target in sepsis rat Source: Annual Congress 2009 - Severe sepsis and multiple organ failure Year: 2009 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 In vivo imaging of NF-kB pathway in acute lung inflammation mouse model can predict a pharmacological response Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 The promise of mTOR signaling as a therapeutic target for IPF Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference Year: 2020 Preventive and therapeutic effects of phosphoinositide 3-kinase inhibitors on acute lung injury Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury Year: 2011 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 Febrile-range hyperthermia augments lung injury through a mechanism involving death receptor signaling Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 Targeting metabolic reprogramming as a novel anti-fibrotic strategy Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease Year: 2019 Amifostine reduces lipopolysaccharide-induced lung dysfunction via suppression of redox-sensitive inflammatory signaling Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016 miR-184 mediates hyperoxia-induced injury by targeting cell death and angiogenesis signalling pathways in the developing lung Source: Eur Respir J, 58 (3) 1901789; 10.1183/13993003.01789-2019 Year: 2021 Amelioration of hyperoxia-induced lung injury using a sphingolipid-based intervention Source: Eur Respir J 2013; 42: 776-784 Year: 2013 A novel approach for optimal lung recruitment in acute lung injury Source: Annual Congress 2005 - Pulmonary function outcome, respiratory morbidity in prematurely born children and acute lung injury Year: 2005 PKA- and Epac/Rap-dependent mechanisms of lung endothelial barrier protection in acute lung injury Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury Year: 2009 Modulation of oxidative stress pathway by arginase inhibition: Evaluation in an animal model of chronic pulmonary inflammation Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 Hsp90 binding inhibitors improve survival in a murine model of sepsis induced acute lung injury Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006